June 2016, Vol. 5, No. 5
Personalized Medicine in Oncology: Expanding Our Knowledge of Precision MedicineLetter to Our Readers
This issue of Personalized Medicine in Oncology (PMO) is a testament to how far we’ve come in our understanding of, and novel approaches to, the treatment of cancer. Armed with knowledge of molecular biomarkers, genetic mutations, genomics, immunotherapeutics, and targeted therapies, we are better able to treat patients with cancer to obtain longer survival and higher quality of life than ever before.
This month, Christos Fountzilas, MD, and Virginia G. Kaklamani, MD, DSc, provide a review of BRAF mutations and implications when considering treatment strategies for patients with this mutation.
In our Interview with the Innovators department, we talk with Chief Scientific Officer Paul W. Dempsey, PhD, and Chief Medical Officer Paul Y. Song, MD, of Cynvenio about their multiple-template strategy that analyzes DNA from circulating tumor cells, circulating cell-free DNA in blood, and tissue biopsies, as well as the initiation of their clinical trial in triple-negative breast cancer. We hope you find our exchange insightful and helpful.
Is there a topic you would like to see discussed in PMO? An innovator in the oncology community you’d like to have interviewed? Please contact us with your comments and request at firstname.lastname@example.org.
As always, thank you for your loyal readership. It is our pleasure to serve you in your quest to provide personalized medicine to your patients.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
An ongoing trial of a novel strategy to evaluate new regimens for early-stage breast cancer has identified another neoadjuvant combination worthy of a phase 3 trial involving patients with HER2-positive disease. The combination of ado-trastuzumab emtansine (T-DM1) and pertuzumab resulted in an estimated pathologic complete response (pCR) rate of 52% [ Read More ]
The following are a selection of key clinical trials that are currently recruiting patients for inclusion in investigations of new therapies or new combinations of available therapies for patients with colorectal cancer. Each clinical trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. The information [ Read More ]